AVROBIO, Inc.

NASDAQ:AVRO

1.4 (USD) • At close June 20, 2024
Bedrijfsnaam AVROBIO, Inc.
Symbool AVRO
Munteenheid USD
Prijs 1.4
Beurswaarde 5,237,596
Dividendpercentage 0%
52-weken bereik 1.38 - 19.8
Industrie Biotechnology
Sector Healthcare
CEO Mr. Erik John Ostrowski M.B.A.
Website https://www.avrobio.com

An error occurred while fetching data.

Over AVROBIO, Inc.

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective

Vergelijkbare Aandelen

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

0.841 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

5.77 USD

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.315 USD

Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

ONCT

0.527 USD

Evogene Ltd. logo

Evogene Ltd.

EVGN

1.65 USD

Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc.

MBRX

1.65 USD

Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP

12.75 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)